ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland). This subsidy will support a groundbreaking consortium led by ParaMedir in their mission to improve healthcare through innovative (bio)monitoring solutions. Next to the subsidy granted by the SNN, the province of Groningen and the municipality of Groningen have both agreed to finance this project as well, contributing about €130,000.00, underlining the importance of this project for the region.
The consortium, consisting of valued partners including the University Medical Centre Groningen (UMCG), Health Hub Roden, and GitGud Software Development, aims to address the urgent challenge of diagnosing and monitoring patients with acute heart failure. Acute heart failure affects 25 million patients globally, with rising incidence and high hospitalization rates. The readmission rate is alarming, and the mortality rate is significant. The standard treatment approach involves restoring the patient's fluid balance using diuretics to eliminate salt and fluid from the patient's body. Currently, treatment of acute heart failure relies on frequent urine collections analyzed through conventional methods.
Cardiodrop©, a groundbreaking innovation, will enable rapid and frequent bedside urine analysis. Building on ParaMedir’s proprietary technology, CardioDrop© will be optimized for use in acute heart failure patients. It facilitates personalized treatment in cardiac care units (CCUs) and intensive care units (ICUs) by monitoring biomarkers and electrolytes. Cardiodrop's implementation in CCUs and ICUs will significantly enhance the quality of life for acute heart failure patients and their caregivers. It will reduce mortality rates, readmissions, and healthcare costs. Additionally, it enables early detection and treatment of renal failure, revolutionizing care provision and improving well-being.
The EFRO subsidy awarded by SNN in the Northern Netherlands is a proof of the consortium's dedication to advancing medical technology and improving patient care. ParaMedir extends its gratitude to SNN and the consortium partners for their commitment and collaborative efforts.
ParaMedir is an innovative medical technology company based in the North of the Netherlands. By developing innovative (bio)monitoring solutions that seamlessly integrate into patient care, ParaMedir aims to revolutionize the healthcare industry. Through the fusion of two promising technologies - biosensing and microfluidics - Paramedir has developed a robust platform that enables real-time continuous monitoring of crucial biomarkers. The first product in development is UriMoni™, a diagnostic device developed for bedside monitoring and prediction of Acute Kidney Injury (AKI).
UriMoni™ and CardioDrop© comprises an array of micro(bio)sensors that monitor relevant biomarkers. These electrochemical micro(bio)sensors, assembled based on extensive ParaMedir intellectual property, provide selective and sensitive measurements of key urinary biomarkers. Proprietary algorithms convert the electrochemical output into biochemical and clinically relevant information, enabling doctors to assess kidney function for the diagnosis and monitoring of acute kidney injury (AKI) and acute heart failure (AHF).
ParaMedir envisions a future where the obtained information is seamlessly uploaded to the hospital management system (HIS), making it accessible to relevant clinical personnel at any given time. Additionally, the integration of AI solutions holds the potential for predicting kidney function and managing AKI and AHF more effectively. The higher temporal resolution of kidney function biomarkers allows for the detection of short-term changes, leading to improved management strategies. For more information about ParaMedir and its revolutionary products, please visit www.Paramedir.nl

Source article and picture: Paramedir
With the launch of LIFE Capital, the Northern Netherlands gains a powerful collaboration platform that brings together companies, talent, and knowledge institutions in the fast-growing Life Sciences & Health sector. During a special launch dinner on Tuesday, November 25 at LIFE Cooperative member Polyvation on the Groningen Campus, not only was the new brand unveiled, but an ambitious vision for the future was also presented. LIFE Capital, formerly LIFE Academy, marks the next phase of the LIFE Cooperative: shifting from a focus on training alone to a broadly supported collaboration platform for human capital. “With LIFE Capital we are taking the next step in strengthening our sector,” says Melloney Dröge, board member of the LIFE Cooperative. “We are bringing companies, talent, and knowledge together into one ecosystem where growth, learning, and innovation go hand in hand. We are aiming for a joint approach to the human capital challenges of our sector. In this way, we are building a region where you can truly move forward for a lifetime, literally and figuratively.”From LIFE Academy to LIFE Capital The transition from LIFE Academy to LIFE Capital is more than a name change. The new brand reflects the organization’s growth and its ambition to look beyond training alone. LIFE Capital will become the linchpin of human capital in the Life Sciences & Health sector: it connects talent, companies, and knowledge, accelerates collaboration, and strengthens the position of the Northern Netherlands as a breeding ground for innovation and talent. A long and healthy life: that is ultimately what Life Sciences & Health is all about. Thanks to innovations from companies in this sector, diseases are detected sooner, treated more effectively, and sometimes even prevented. From breakthrough therapies to keeping healthcare affordable and accessible, the business community acts as the engine behind life-changing progress. LIFE Capital aims to strengthen that foundation by investing in people, knowledge, and collaboration. “LIFE Capital helps companies move forward, but also strengthens the image and visibility of our sector,” says Sven Stielstra, Manager of LIFE Capital. “In this way, we show what Life Sciences & Health truly stands for and make the sector attractive to new talent and innovative companies. Over the next ten years, we will attract €50 million for human capital. In this first year alone, we have already realized €6.6 million through regional and national funds.”Looking ahead: recruitment campaign and pilots in 2026 Today, the day after the launch dinner, LIFE Capital’s recruitment campaign begins. This campaign focuses on attracting participants for the first pilot modules, which will start in spring 2026. These modules were developed thanks to an intensive and unique collaboration between Hanze, UMCG, and various companies within the sector. By combining knowledge and practical experience, top-notch programmes have been created that will be tested in the coming period. After the pilot phase, the modules will be further developed and made more widely available later in 2026 to everyone in the Northern Netherlands who wishes to contribute to a strong Life Sciences & Health ecosystem.About LIFE Capital LIFE Capital is the collaboration platform of the LIFE Cooperative, a network of more than 60 companies in the Life Sciences & Health sector. The platform connects organisations around shared human capital challenges and develops solutions that attract, develop, and retain talent. What started ten years ago as separate initiatives within the cooperative has grown into a strategic programme in which companies, knowledge institutions, and governments work together on a structural basis. With activities ranging from joint training and HR networks to new educational programmes and labour market research, LIFE Capital works towards one goal: a strong, agile region in which talent in life sciences & health can continue to grow with the right skills. Move people forward.About LIFE Cooperative The LIFE Cooperative stimulates innovation in the life sciences by facilitating collaboration between entrepreneurs, researchers, and investors. Through various programmes and events, LIFE promotes the development of technologies that improve health and well-being. The cooperative represents more than 60 companies in the Northern Netherlands, ranging from ambitious startups and innovative SMEs to international players. Together, they represent approximately 5,000 FTEs and a turnover of €500 million.
Accelerating Sustainability in Healthcare Paulina Snijders, member of the UMCG Executive Board, and Bart Volkers, director of the Circular Groningen Drenthe Association (VCGD), opened the executive network meeting. They emphasized the importance of cooperation between all partners. Artist Maria Koijck delivered an inspiring keynote on visualizing hospital waste. UMCG Chief Green Officer Schelto Kruijff outlined opportunities to accelerate sustainability in healthcare, sharing inspiring examples such as the use of a washable, reusable insulation gown. Project leaders Sven Jurgens and Femke van der Zant described how the consortium has significantly developed in recent times.Various Work Packages The executives exchanged extensive experience and knowledge, and the Care2Change work package leaders presented posters. The work packages focus on areas such as redesigning single-use healthcare products and mapping the CO₂ emissions of products. Sven Jurgens said: “Care2Change is the starting point for continued collaboration on making healthcare more sustainable. How valuable it would be if, through this collaboration, we could provide a blueprint for others to inspire them to go green as well.”Northern Netherlands as an Example Hanneke Bouwsema, secretary to the special government representative for the circular economy at the Ministry of Infrastructure and Water Management, emphasized the importance of starting small and recognizing the sustainable initiatives that are already working well. She described the Northern Netherlands as a “role model” for The Hague when it comes to making healthcare more sustainable.About the Care2Change Consortium Care2Change is a collaboration between UMCG, University of Groningen, Martini Hospital, Sterinoord, GS1/EAN Netherlands, Boikon, Ommelander Hospital, Treant, Frisius MC, NHL Stenden, Hanze University of Applied Sciences, Circular Friesland Association, LIFE Cooperative, Circular Groningen Drenthe Association, Green Chemistry Drenthe Business Network (SUSPACC), Milieuplatform Zorg, Nij Smellinghe, Pezy Product Design, 8D Games, House of Design, Antonius Hospital, NOM, Menzis, De Friesland, Ecoras, BBENG, the provinces of Groningen and Drenthe, and the municipalities of Groningen, Assen, Leeuwarden and Emmen. The project is partly funded by SNN’s ERDF resources, with co-financing from the participating organizations.More Information Want to know more about Care2Change and the consortium? Read: UMCG trots op nieuwe samenwerking die uitstoot terugdringt: Care2change Source article: Care2Change
Recently, the LIFE Cooperative, together with the University Medical Center Groningen (UMCG), has been working hard on submitting projects to PharmaNL.